)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Adocia
Adocia (ADOC) investor relations material
Adocia Q2 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 TU earnings summary23 Jul, 2026
Executive summary
Cash position at €9.7 million as of June 30, 2026, with a secured runway into early Q2 2027 following a shareholder loan agreement with Vester Finance.
Focused development on BioChaperone® platform, with positive feasibility study results and ongoing discussions with major pharmaceutical companies.
Board changes included the departure of the co-founder and appointment of a new independent director.
Financial highlights
Q2 2026 revenue was €43,000, attributed to a feasibility study with a potential partner; no licensing or research agreement revenue.
Cash position declined from €17.2 million at year-end 2025 to €9.7 million at June 30, 2026.
Cash burn for H1 2026 was €10.1 million, down from €11.8 million in H1 2025 (excluding financing).
Net financial debt includes €0.7 million in state-guaranteed loans and €0.7 million in shareholder advances.
Potential for up to €21.7 million in gross proceeds if all outstanding warrants are exercised.
Outlook and guidance
Financing secured into early Q2 2027, not accounting for potential new partnership revenues.
Focus remains on advancing BioChaperone® programs and leveraging positive feasibility results for new collaborations.
Timeline for BioChaperone Lispro China filing
M1Pram strategy after Sanofi deal expiration
Status of BioChaperone talks with large pharma
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adocia
- BC Lispro/BCLIS achieved superior postprandial and daily glucose control with non-inferior HbA1c.ADOC
Study result22 Jun 2026 - Innovative peptide platforms drive growth in diabetes and obesity therapeutics.ADOCInvestor presentation22 Jun 2026
- Cash runway secured to Q2 2027; BioChaperone® prioritized after positive study results.ADOCQ1 2026 TU12 May 2026
- Pipeline advances and new financing extend cash runway to Q2 2027 despite wider net loss.ADOCH2 202521 Apr 2026
- Strong clinical progress, robust cash, and leadership changes mark a transformative quarter.ADOCQ4 2025 TU24 Feb 2026
- Strong cash position, positive Phase 3 results, and advancing R&D drive future growth.ADOCQ3 2025 TU15 Oct 2025
- Net loss of €9.3M in H1 2025, cash runway extended to Q2 2026 after capital raise and milestone.ADOCH1 202529 Sep 2025
- Cash position strengthened and pipeline progress set stage for key milestones in 2025.ADOCH1 2025 TU23 Jul 2025
- Innovative peptide delivery platforms advance late-stage diabetes and obesity treatments.ADOCInvestor Presentation27 Jun 2025
Next Adocia earnings date
Q2 202624 Sep, 2026
Adocia
Next Adocia earnings date
Q2 202624 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage